Skip to content
Save up to 80%

Prasugrel

Quality products
24/7 Support
Fast delivery
Delivery from 4 days
Select pack Package Per unit Price

Free delivery on orders from R 3 930.00, free express delivery from R 5 895.00

Secure Payments
Track your order
Best price guarantee

Prasugrel is an oral antiplatelet medicine for adults with acute coronary syndrome undergoing PCI. Used with aspirin, it helps prevent clot-related heart attack and stent thrombosis by reducing platelet activation.

Description

Prasugrel is an oral P2Y12 antiplatelet medicine for adults with acute coronary syndrome undergoing percutaneous coronary intervention. It contains the active ingredient prasugrel and belongs to the thienopyridine antiplatelet class.

Composition

Prasugrel contains the active ingredient prasugrel. It belongs to the thienopyridine class of oral P2Y12 antiplatelet medicines and reduces platelet activation.

Dosage and usage

Prasugrel is taken orally according to the cardiologist’s prescribed regimen. Treatment may begin with a loading dose around the time of PCI, followed by maintenance treatment. Aspirin is commonly continued at the same time as part of dual antiplatelet therapy. The dose is stated on the pack — follow the leaflet.

The correct regimen depends on the clinical presentation, planned PCI, bleeding risk, and other medicines. The prescribing team selects the strength and duration for the individual patient. The dose is stated on the pack — follow the leaflet.

Typical administration principles include:

  • Take the prescribed tablet by mouth according to the maintenance instructions.
  • Swallow the tablet with water.
  • Follow the schedule stated on the pack and in the leaflet.
  • Continue aspirin only at the dose selected by the treating cardiology team.
  • Do not double the next dose after a missed dose.
  • If a dose is missed, follow the instructions in the leaflet or those given by the prescriber.
  • Do not stop prasugrel suddenly after coronary stenting without a documented clinical plan.
  • Tell every doctor, dentist, anaesthetist, and emergency clinician that prasugrel is being used.

The dose is stated on the pack — follow the leaflet. Treatment in older adults or people with increased bleeding risk requires individual assessment by the prescribing team.

Morphine can delay absorption of oral antiplatelet medicines during acute coronary syndrome. This can make the early antiplatelet effect less predictable, so the hospital team may adjust the treatment plan.

A missed dose should never be replaced with two tablets. Taking an extra dose can increase bleeding without reliably restoring the intended antiplatelet effect.

The duration of treatment is determined by the cardiology team. Follow the prescribed duration and the instructions in the leaflet.

Before any planned operation, dental extraction, endoscopy, or invasive procedure, the treating team needs to know that prasugrel has been prescribed. Stopping it without a cardiology plan can increase the risk of stent thrombosis.

How it works

Prasugrel is converted in the body to an active metabolite. This metabolite binds irreversibly to the platelet P2Y12 receptor, which is activated by adenosine diphosphate (ADP). Blocking this receptor reduces platelet activation and interferes with the final steps required for platelet aggregation.

The practical result is reduced fibrinogen binding between platelets. Platelets become less able to form and strengthen a clot at the site of a ruptured coronary plaque or newly placed stent.

The effect lasts for the remaining life of affected platelets. New platelets must be produced before normal platelet reactivity returns, which is why bleeding can continue after the last dose.

Indications

Prasugrel is a thienopyridine P2Y12 inhibitor. It belongs to the antiplatelet class and is used in acute coronary syndrome, including unstable angina and myocardial infarction treated with percutaneous coronary intervention (PCI). PCI uses a catheter to open a narrowed or blocked coronary artery, often with placement of a stent.

After a coronary stent is inserted, activated platelets can attach to the treated area and form a clot. Prasugrel reduces this platelet response. It is prescribed alongside aspirin as dual antiplatelet therapy when the expected reduction in coronary clotting outweighs the risk of bleeding.

Clinical guidance from the European Medicines Agency supports prasugrel use in selected adults with acute coronary syndrome managed with PCI [1]. The medicine is not intended for routine prevention in people without an acute coronary indication.

Comparison

Prasugrel, ticagrelor, and clopidogrel all reduce platelet activation through the P2Y12 pathway, but they differ in activation, onset, reversibility, and bleeding profile.

P2Y12 inhibitor Pharmacological profile Clinical trade-off
Prasugrel Irreversible thienopyridine; active metabolite formed after hepatic activation Potent, consistent inhibition with increased bleeding risk in vulnerable groups
Ticagrelor Reversible, direct-acting P2Y12 inhibitor Rapid inhibition; dyspnoea and bleeding can limit treatment
Clopidogrel Irreversible thienopyridine requiring hepatic activation Less potent and more variable response; may be preferred when bleeding risk is higher

Prasugrel is often selected when rapid, reliable platelet inhibition is needed during PCI and the patient does not have a history of stroke or transient ischaemic attack. Ticagrelor can provide rapid inhibition without the same metabolic activation pathway, though breathlessness and twice-daily dosing may affect continuation.

Clopidogrel has a longer history of use and may be chosen when bleeding risk, age, drug cost, comorbidity, or the need for oral anticoagulation changes the treatment balance. Genetic differences and drug interactions can reduce its activation in some patients.

Switching between P2Y12 inhibitors is a specialist decision. It may occur after bleeding, breathlessness, surgery planning, treatment intolerance, recurrent ischaemia, or a change in the assessed risk of stent thrombosis.

The choice is not based on potency alone. Bleeding needs attention. Dosing follows the prescription. Timing matters after PCI. The prescriber weighs coronary risk against the patient’s likelihood of serious bleeding.

Contraindications

Prasugrel is generally contraindicated in the following situations:

  • Active pathological bleeding.
  • Previous stroke or transient ischaemic attack.
  • A known serious hypersensitivity to prasugrel or an excipient.
  • A clinical situation in which uncontrolled bleeding would pose an unacceptable danger.
  • Severe hepatic impairment when the product information identifies treatment as unsuitable.

When this is not for you

Prasugrel is NOT for you if you have had a previous stroke or transient ischaemic attack, active pathological bleeding, or a serious hypersensitivity to the medicine.

A prior stroke or transient ischaemic attack is a major restriction because prasugrel can increase the risk of intracranial haemorrhage in this group. The contraindication applies even when the neurological event occurred years earlier.

Severe hepatic impairment can alter drug handling and increase the consequences of bleeding. Mild or moderate liver problems may require individual assessment rather than automatic exclusion.

Patients aged 75 years or older need careful selection. Low body weight, anaemia, previous gastrointestinal bleeding, kidney disease, uncontrolled hypertension, and a planned operation can all shift the balance toward harm.

Pregnancy and breastfeeding require an individual risk assessment. The cardiovascular danger of stopping antiplatelet treatment after PCI may be substantial, so treatment changes should be coordinated with the cardiology and obstetric teams.

Side effects

Bleeding is the main safety concern with prasugrel. Because platelet inhibition is potent and irreversible, bleeding may be more frequent or more difficult to control than with less potent antiplatelet treatment. The TRITON-TIMI 38 trial found fewer ischaemic events with prasugrel than clopidogrel in selected acute coronary syndrome patients undergoing PCI, alongside more major bleeding [2].

Common or clinically relevant bleeding sites include:

  • Bruising and larger-than-usual haematomas.
  • Bleeding from an arterial puncture site in the wrist or groin.
  • Nosebleeds or bleeding from the gums.
  • Gastrointestinal bleeding.
  • Blood in urine.
  • Prolonged bleeding from small cuts.
  • Intracranial bleeding, which is uncommon but potentially fatal.

Seek urgent medical attention for vomiting blood, black or tarry stools, coughing blood, sudden severe headache, weakness on one side, confusion, fainting, new speech difficulty, or bleeding that does not stop with firm pressure.

Non-bleeding adverse effects can include headache, back pain, high blood pressure, nausea, and shortness of breath. Some symptoms may arise from the underlying coronary condition rather than from prasugrel itself, so a sudden change should be assessed promptly.

One practical detail is easy to miss: a small bruise at a catheter access site can enlarge several hours after discharge. Increasing swelling, severe pain, numbness, or a cold hand or foot needs urgent assessment because it may indicate a vascular complication.

For a minor cut, apply continuous firm pressure with clean gauze. Releasing pressure repeatedly to check the wound can prolong bleeding when platelet inhibition is active.

The risk rises when prasugrel is combined with warfarin, heparin, another anticoagulant, non-steroidal anti-inflammatory drugs, or medicines that affect clotting. Alcohol can also worsen bleeding risk when intake is heavy or regular.

Common mistakes

Several recurring mistakes reduce the benefit of prasugrel or increase harm:

  • Stopping treatment after bruising without contacting the cardiology team.
  • Taking two tablets after a missed dose.
  • Forgetting to mention prasugrel before dental treatment or surgery.
  • Using ibuprofen or naproxen for pain without checking the combination.
  • Assuming that a small amount of blood in the stool or urine is harmless.
  • Taking aspirin from more than one combination product.
  • Failing to tell emergency clinicians about a recent coronary stent.
  • Treating a remote transient ischaemic attack as irrelevant.
  • Continuing heavy alcohol intake despite repeated bleeding symptoms.
  • Confusing once-daily maintenance treatment with the initial loading regimen.

One detail matters after PCI: a patient may feel well while the stent is healing, but the absence of symptoms does not mean antiplatelet treatment can be stopped safely.

What doctors say

In clinical practice, cardiologists usually describe prasugrel as a high-potency option for a defined PCI population rather than a general-purpose blood thinner. It is most useful when prevention of coronary platelet clotting is a priority and major bleeding risk is acceptable.

A prescriber will usually confirm three points before treatment:

  • Whether PCI is planned or has already occurred.
  • Whether the patient has ever had a stroke or transient ischaemic attack.
  • Whether age, body weight, anaemia, kidney disease, liver disease, or other medicines raise bleeding risk.

The medicine works best when taken consistently. Missing repeated doses can reduce protection against stent thrombosis, while taking extra doses can produce dangerous bleeding.

A patient who develops new chest pain, fainting, neurological symptoms, or uncontrolled bleeding needs emergency care rather than a routine medication review.

Frequently asked questions

Is Prasugrel used with aspirin?

Prasugrel is commonly combined with aspirin as dual antiplatelet therapy after acute coronary syndrome and PCI. The 2024 EMA product information describes this combination as part of the treatment approach for selected patients . The treatment plan includes a prescribed initial dose followed by maintenance dosing, with duration determined by coronary and bleeding risks.

How does Prasugrel reduce stent thrombosis?

Prasugrel produces an active metabolite that irreversibly blocks platelet P2Y12 receptors. The 2023 FDA prescribing information explains that this reduces ADP-mediated platelet activation and aggregation [3]. Less platelet aggregation lowers the chance of clot formation around a newly placed coronary stent, while the same action increases bleeding risk.

Can a person with a previous stroke take Prasugrel?

A previous stroke or transient ischaemic attack is a contraindication to prasugrel in the 2024 EMA product information. The restriction remains relevant when the event happened many years earlier because intracranial bleeding risk can outweigh the coronary benefit. A cardiology team must select another antiplatelet strategy when this history is present.

Does Prasugrel require a kidney dose adjustment?

The dose is not normally adjusted solely because of reduced kidney function, but kidney disease can increase total bleeding risk. The 2021 WHO guidance describes chronic kidney disease as a factor that can complicate antithrombotic treatment decisions [4]. Age, anaemia, body weight, previous bleeding, and concurrent anticoagulants also influence the final regimen.

Can Prasugrel be taken before surgery?

Planned surgery may require a carefully timed interruption because platelet inhibition persists after the last tablet. The 2023 FDA label advises a treatment interruption before surgery when clinically possible, balanced against the danger of stent thrombosis . The surgeon, anaesthetist, and cardiologist need the same medication history before deciding when treatment should stop and restart.

Does Prasugrel cause shortness of breath?

Shortness of breath is less characteristic of prasugrel than of ticagrelor, but it can occur in people with acute coronary disease, heart failure, anaemia, or another medical problem. The 2023 NICE guidance on acute coronary syndromes emphasises assessment of new or worsening breathlessness in this setting [5]. Sudden breathlessness with chest pain, fainting, or sweating requires emergency assessment.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Prasugrel: Reviews and Experiences

3.9
Based on 4 reviews
Ama, 62 Cape Town 1 month
Verified
Rating: 4 out of 5

I took prasugrel after a stent and noticed bruises on both forearms during the first month. They looked alarming but did not hurt. The cardiology team told me not to stop the tablets and arranged a review.

18 Oct 2026
Thabo, 64 Durban 2 months
Verified
Rating: 4 out of 5

The treatment was straightforward once I linked it to my morning routine. I had a nosebleed that lasted longer than usual after gardening, so I stopped using anti-inflammatory pain tablets and contacted the clinic.

28 Oct 2026
Michael, 58 Johannesburg 3 months
Verified
Rating: 3.5 out of 5

I had been prescribed prasugrel after an acute coronary event. It worked as part of the hospital plan, but the bleeding precautions affected everyday activities, especially shaving and contact sports.

06 Nov 2026
Anika, 61 Gqeberha 1 month
Verified
Rating: 4 out of 5

I missed a dose during a weekend away and nearly doubled the next one. The pharmacist-led clinic advised me to follow the scheduled regimen instead. I now keep a written medicine list in my wallet.

14 Nov 2026

Sources

  1. European Medicines Agency (2024). Efient: Summary of Product Characteristics (prasugrel).
  2. The New England Journal of Medicine (2007). Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes.
  3. U.S. Food and Drug Administration (2023). Effient (prasugrel) Prescribing Information.
  4. World Health Organization (2021). WHO guideline for the pharmacological treatment of hypertension in adults.
  5. National Institute for Health and Care Excellence (2023). Acute coronary syndromes: diagnosis and management.
Get our free app Shop faster and track your orders 4.0 · 598 reviews Install